TKTimothy E. G. Krueger

Timothy E. G. Krueger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Timothy E. G. Krueger has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Targeting interleukin 4 receptor alpha on tumor-associated macrophages reduces the pro-tumor macrophage phenotype

    by Amber E. de Groot, Kayla V. Myers, Timothy E.G. Krueger, W. Nathaniel Brennen, Sarah R. Amend, Kenneth J. Pienta


  • Open Access

    Characterization of tumor‐associated macrophages in prostate cancer transgenic mouse models

    by Amber E. de Groot, Kayla V. Myers, Timothy E. G. Krueger, Ashley L. Kiemen, Natalia H. Nagy, Alexandria Brame, Vicente E. Torres, Zhongyuan Zhang, Levent Trabzonlu, W. Nathaniel Brennen, et al.

    Background: Tumor‐associated macrophages (TAMs) are critical components of the tumor microenvironment (TME) in prostate cancer. Commonly used orthotopic models do not accurately reflect the complete TME of a human patient or the natural initiation and progression of a tumor. Therefore, genetically engineered mouse models are essential for studying the TME as well as advancing TAM‐targeted therapies. Two common transgenic (TG) models of prostate cancer are Hi‐Myc and transgenic adenocarcinoma of the mouse prostate (TRAMP), but the TME and TAM characteristics of these models have not been well characterized.Methods: To advance the Hi‐Myc and TRAMP models as tools for TAM studies, macrophage infiltration and characteristics were assessed using histopathologic, flow cytometric, and expression analyses in these models at various timepoints during tumor development and progression.Results: In both Hi‐Myc and TRAMP models, macrophages adopt a more pro‐tumor phenotype in higher histological grade tumors and in older prostate tissue. However, the Hi‐Myc and TRAMP prostates differ in their macrophage density, with Hi‐Myc tumors exhibiting increased macrophage density and TRAMP tumors exhibiting decreased macrophage density compared to age‐matched wild type mice.Conclusions: The macrophage density and the adenocarcinoma cancer subtype of Hi‐Myc appear to better mirror patient tumors, suggesting that the Hi‐Myc model is the more appropriate in vivo TG model for studying TAMs and TME‐targeted therapies.


  • Overcoming Stromal Barriers to Immuno-Oncological Responses via Fibroblast Activation Protein-Targeted Therapy

    by W Nathaniel Brennen, Daniel L J Thorek, Wen Jiang, Timothy E Krueger, Lizamma Antony, Samuel R Denmeade, John T Isaacs

    The tumor microenvironment contributes to disease progression through multiple mechanisms, including immune suppression mediated in part by fibroblast activation protein (FAP)-expressing cells. Herein, a review of FAP biology is presented, supplemented with primary data. This includes FAP expression in prostate cancer and activation of latent reservoirs of TGF-β and VEGF to produce a positive feedback loop. This collectively suggests a normal wound repair process subverted during cancer pathophysiology. There has been immense interest in targeting FAP for diagnostic, monitoring and therapeutic purposes. Until recently, this development has outpaced an understanding of the biology; impeding optimal translation into the clinic. A summary of these applications is provided with an emphasis on eliminating tumor-infiltrating FAP-positive cells to overcome stromal barriers to immuno-oncological responses.